Minnesota is currently home to 2107 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
NCT04573023
Recruiting
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
Gender:
ALL
Ages:
All
Trial Updated:
05/14/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Mucopolysaccharidosis II
Register for Updates
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
NCT06411795
Recruiting
This phase II trial compares the effect of rectus sheath block with liposomal bupivacaine to thoracic epidural analgesia (TEA) on pain control in patients following surgical removal of all or part of the pancreas and duodenectomy (pancreatoduodenectomy). Administering long acting local anesthetics, such as liposomal bupivacaine, in between the muscle layers of the abdomen (rectus sheath block) may help with pain relief during and after surgery. TEA uses a needle to insert a flexible plastic cath... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Duodenal Neoplasm, Pancreatic Neoplasm
Register for Updates
Lung Ultrasound - Prospective Study
NCT06140615
Recruiting
The goal of this clinical trial is to determine whether lung ultrasound can predict extubation success in neonates with respiratory distress. Participants will undergo a lung ultrasound pre- and post-extubation.
Gender:
ALL
Ages:
6 months and below
Trial Updated:
05/13/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Respiratory Distress of Newborn
Register for Updates
A Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT05914116
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Research Site 121, Saint Paul, Minnesota
Conditions: Advanced Solid Tumors
Register for Updates
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
NCT05911763
Recruiting
This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/13/2025
Locations: M Health Fairview- Masonic Cancer Clinic - Clinics- Site Number : 8400010, Minneapolis, Minnesota
Conditions: Hemophilia A
Register for Updates
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
NCT04291612
Recruiting
This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Mayo Clinic (Data Collection and Data Analysis), Rochester, Minnesota
Conditions: Endometrial Cancer, Endometrioid Adenocarcinoma, Endometrial Cancer Stage I
Register for Updates
The Dragon PLC Trial (DRAGON-PLC)
NCT06914648
Recruiting
The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specifically focuses on patients with hepatocellular carcinoma and cholangiocarcinoma. The main questions this trial aims to answer are whether combined PVE and HVE increases the proportion of patients who be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Primary Liver Cancer, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Register for Updates
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
NCT06566209
Recruiting
The purpose of this pilot study is to evaluate Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET) as an imaging modality to diagnose and risk stratify subclinical, imaging negative ICI-myocarditis, and to determine whether subclinical ICI-induced myocarditis is a distinct and clinically relevant entity with a risk of progression to fulminant myocarditis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Subclinical Immune Checkpoint Inhibitor-Induced Myocarditis, Myocarditis, ICI-Myocarditis, Solid Malignant Tumor, Hematologic Malignancy, Subclinical Myocarditis, Subclinical ICI-myocarditis
Register for Updates
Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
NCT06386315
Recruiting
This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota
Conditions: Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma
Register for Updates
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a and 2) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
NCT05271318
Recruiting
This is an open-label, phase 1/2, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
Register for Updates
The COCOA-PAD II Trial
NCT04794530
Recruiting
Among people with peripheral artery disease (PAD) age 55 and older, the investigators will test the hypothesis that PAD participants randomized to cocoa flavanols will have greater improvement or less decline in six-minute walk distance at six-month follow-up, compared to those randomized to placebo. The study will randomize 190 participants with PAD age 55 and older to one of two groups for six months: cocoa flavanols vs placebo. Our primary outcome is change in six-minute walk distance at six-... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
05/12/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Peripheral Artery Disease
Register for Updates
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
NCT04580420
Recruiting
The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
Gender:
ALL
Ages:
All
Trial Updated:
05/12/2025
Locations: Clinical Trial Site, Rochester, Minnesota
Conditions: End Stage Renal Disease, Primary Hyperoxaluria Type 1
Register for Updates